Evidence map›Paper›PMID 36983573›Full record

ArticleJournal of personalized medicine2023

Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection.

Patricia-Andrada Reștea, Mariana Mureșan, Adrian Voicu, Tunde Jurca, Annamaria Pallag, Eleonora Marian, Laura Grațiela Vicaș, Ionuț I Jeican, Carmen-Bianca Crivii

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Patricia-Andrada ReșteaDepartment of Preclinical Discipline, Doctoral School of Biomedical Science, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.ORCID 0000-0001-9264-0838
Mariana MureșanDepartment of Preclinical Discipline, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Adrian VoicuDepartment II, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Tunde JurcaDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.ORCID 0000-0001-5591-7826
Annamaria PallagDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.ORCID 0000-0002-7146-3040
Eleonora MarianDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Laura Grațiela VicașDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.ORCID 0000-0001-5328-333X
Ionuț I JeicanDepartment of Morphological Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0000-0002-3465-9474
Carmen-Bianca CriviiDepartment of Morphological Sciences, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0000-0001-5275-5753
University of Oradea · ROIuliu Hațieganu University of Medicine and Pharmacy · ROVictor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 viral infection is a current and important topic for patients with comorbidities of type 2 diabetes and obesity, associated with increased risk of mortality and morbidity. This study aims to analyze, compare and describe admission parameters in patients with type 2 diabetes, obesity, and SARS-CoV-2 infection based on whether they received insulin therapy before hospital admission.

methodsOur study enrolled patients diagnosed with type 2 diabetes, obesity, and SARS-CoV-2 viral infection, 81 patients without insulin treatment before hospital admission, and 81 patients with insulin at "Gavril Curteanu" Municipal Clinical Hospital of Oradea, Romania, between August 2020 and March 2022. RT-PCR/rapid antigen tests were used for detecting SARS-CoV-2 viral infection.

resultsThe severe form of COVID-19 was found in 66% of all patients (65% in the group without insulin and 67% in the group with insulin). Oxygen saturation at the time of hospital admission was greater or equal to 90% in 62% of all patients. The most associated comorbidities we founded in this study were: hypertension in 75% of all patients (grade two hypertension 63% in the group without insulin and 64% in the group with insulin), ischemic heart disease in 35% of patients (25% in the group without insulin and 44% in the group with insulin,

conclusionsAntidiabetic therapy taken before hospital admission did not protect patients against cytokine storm in COVID-19, but is very important in the pathophysiological stage of comorbidities. Paraclinical parameters at hospitalization showed differences in correlation with oral antidiabetic treatment like metformin or insulin therapy. Changing the antidiabetic treatment for a small percentage of patients in the group who had not been receiving insulin therapy before discharge was necessary. It is necessary for future studies to see all changes involved in antidiabetic treatment in patients with diabetes type 2 and obesity after SARS-CoV2 viral infection and its long-term evolution.

Indexed as

admission parametersCOVID-19cytokine stormdiabetesinsulin therapyobesitySARS-CoV-2

Identifiers

PMID36983573
PMCPMC10055907
OpenAlexW4321786772

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.